Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Copy number alterations in small intestinal neuroendocrine tumors determined by array comparative genomic hybridization

Authors: Jamileh Hashemi, Omid Fotouhi, Luqman Sulaiman, Magnus Kjellman, Anders Höög, Jan Zedenius, Catharina Larsson

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Small intestinal neuroendocrine tumors (SI-NETs) are typically slow-growing tumors that have metastasized already at the time of diagnosis. The purpose of the present study was to further refine and define regions of recurrent copy number (CN) alterations (CNA) in SI-NETs.

Methods

Genome-wide CNAs was determined by applying array CGH (a-CGH) on SI-NETs including 18 primary tumors and 12 metastases. Quantitative PCR analysis (qPCR) was used to confirm CNAs detected by a-CGH as well as to detect CNAs in an extended panel of SI-NETs. Unsupervised hierarchical clustering was used to detect tumor groups with similar patterns of chromosomal alterations based on recurrent regions of CN loss or gain. The log rank test was used to calculate overall survival. Mann–Whitney U test or Fisher’s exact test were used to evaluate associations between tumor groups and recurrent CNAs or clinical parameters.

Results

The most frequent abnormality was loss of chromosome 18 observed in 70% of the cases. CN losses were also frequently found of chromosomes 11 (23%), 16 (20%), and 9 (20%), with regions of recurrent CN loss identified in 11q23.1-qter, 16q12.2-qter, 9pter-p13.2 and 9p13.1-11.2. Gains were most frequently detected in chromosomes 14 (43%), 20 (37%), 4 (27%), and 5 (23%) with recurrent regions of CN gain located to 14q11.2, 14q32.2-32.31, 20pter-p11.21, 20q11.1-11.21, 20q12-qter, 4 and 5. qPCR analysis confirmed most CNAs detected by a-CGH as well as revealed CNAs in an extended panel of SI-NETs. Unsupervised hierarchical clustering of recurrent regions of CNAs revealed two separate tumor groups and 5 chromosomal clusters. Loss of chromosomes 18, 16 and 11 and gain of chromosome 20 were found in both tumor groups. Tumor group II was enriched for alterations in chromosome cluster-d, including gain of chromosomes 4, 5, 7, 14 and gain of 20 in chromosome cluster-b. Gain in 20pter-p11.21 was associated with short survival. Statistically significant differences were observed between primary tumors and metastases for loss of 16q and gain of 7.

Conclusion

Our results revealed recurrent CNAs in several candidate regions with a potential role in SI-NET development. Distinct genetic alterations and pathways are involved in tumorigenesis of SI-NETs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Muller-Nordhorn J, Koch M, Rocken C, Rindi G, Ruszniewski P, et al: Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011, 117 (15): 3332-3341. 10.1002/cncr.25855.CrossRefPubMed Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Muller-Nordhorn J, Koch M, Rocken C, Rindi G, Ruszniewski P, et al: Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011, 117 (15): 3332-3341. 10.1002/cncr.25855.CrossRefPubMed
2.
go back to reference Kidd M, Modlin IM: Small intestinal neuroendocrine cell pathobiology: ‘carcinoid’ tumors. Curr Opin Oncol. 2011, 23 (1): 45-52. 10.1097/CCO.0b013e328340d006.CrossRefPubMed Kidd M, Modlin IM: Small intestinal neuroendocrine cell pathobiology: ‘carcinoid’ tumors. Curr Opin Oncol. 2011, 23 (1): 45-52. 10.1097/CCO.0b013e328340d006.CrossRefPubMed
3.
go back to reference Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003, 97 (4): 934-959. 10.1002/cncr.11105.CrossRefPubMed Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003, 97 (4): 934-959. 10.1002/cncr.11105.CrossRefPubMed
4.
go back to reference Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, et al: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008, 9 (1): 61-72. 10.1016/S1470-2045(07)70410-2.CrossRefPubMed Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, et al: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008, 9 (1): 61-72. 10.1016/S1470-2045(07)70410-2.CrossRefPubMed
5.
go back to reference Cunningham JL, de Diaz Stahl T, Sjoblom T, Westin G, Dumanski JP, Janson ET: Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chr & Cancer. 2011, 50 (2): 82-94. 10.1002/gcc.20834.CrossRef Cunningham JL, de Diaz Stahl T, Sjoblom T, Westin G, Dumanski JP, Janson ET: Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chr & Cancer. 2011, 50 (2): 82-94. 10.1002/gcc.20834.CrossRef
6.
go back to reference Järhult J, Landerholm K, Falkmer S, Nordenskjöld M, Sundler F, Wierup N: First report on metastasizing small bowel carcinoids in first-degree relatives in three generations. Neuroendocrinology. 2010, 91 (4): 318-323. 10.1159/000299790.CrossRefPubMed Järhult J, Landerholm K, Falkmer S, Nordenskjöld M, Sundler F, Wierup N: First report on metastasizing small bowel carcinoids in first-degree relatives in three generations. Neuroendocrinology. 2010, 91 (4): 318-323. 10.1159/000299790.CrossRefPubMed
7.
go back to reference Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD: Current status of gastrointestinal carcinoids. Gastroenterology. 2005, 128 (6): 1717-1751. 10.1053/j.gastro.2005.03.038.CrossRefPubMed Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD: Current status of gastrointestinal carcinoids. Gastroenterology. 2005, 128 (6): 1717-1751. 10.1053/j.gastro.2005.03.038.CrossRefPubMed
8.
go back to reference Moertel CG: Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol. 1983, 1 (11): 727-740.PubMed Moertel CG: Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol. 1983, 1 (11): 727-740.PubMed
9.
go back to reference Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK: Carcinoid tumour. Lancet. 1998, 352 (9130): 799-805. 10.1016/S0140-6736(98)02286-7.CrossRefPubMed Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK: Carcinoid tumour. Lancet. 1998, 352 (9130): 799-805. 10.1016/S0140-6736(98)02286-7.CrossRefPubMed
10.
go back to reference de Herder WW: Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). Best Pract & Res Clin gastroenterol. 2005, 19 (5): 705-715. 10.1016/j.bpg.2005.05.007.CrossRef de Herder WW: Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome). Best Pract & Res Clin gastroenterol. 2005, 19 (5): 705-715. 10.1016/j.bpg.2005.05.007.CrossRef
11.
go back to reference Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008, 26 (18): 3063-3072. 10.1200/JCO.2007.15.4377.CrossRefPubMed Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, et al: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008, 26 (18): 3063-3072. 10.1200/JCO.2007.15.4377.CrossRefPubMed
12.
go back to reference Kytölä S, Höög A, Nord B, Cedermark B, Frisk T, Larsson C, Kjellman M: Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol. 2001, 158 (5): 1803-1808. 10.1016/S0002-9440(10)64136-3.CrossRefPubMedPubMedCentral Kytölä S, Höög A, Nord B, Cedermark B, Frisk T, Larsson C, Kjellman M: Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol. 2001, 158 (5): 1803-1808. 10.1016/S0002-9440(10)64136-3.CrossRefPubMedPubMedCentral
13.
go back to reference Zhao J, de Krijger RR, Meier D, Speel EJ, Saremaslani P, Muletta-Feurer S, Matter C, Roth J, Heitz PU, Komminoth P: Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis. Am J Pathol. 2000, 157 (5): 1431-1438. 10.1016/S0002-9440(10)64780-3.CrossRefPubMedPubMedCentral Zhao J, de Krijger RR, Meier D, Speel EJ, Saremaslani P, Muletta-Feurer S, Matter C, Roth J, Heitz PU, Komminoth P: Genomic alterations in well-differentiated gastrointestinal and bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular pathogenesis. Am J Pathol. 2000, 157 (5): 1431-1438. 10.1016/S0002-9440(10)64780-3.CrossRefPubMedPubMedCentral
14.
go back to reference Löllgen RM, Hessman O, Szabo E, Westin G, Åkerstrom G: Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer. 2001, 92 (6): 812-815. 10.1002/ijc.1276.CrossRefPubMed Löllgen RM, Hessman O, Szabo E, Westin G, Åkerstrom G: Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer. 2001, 92 (6): 812-815. 10.1002/ijc.1276.CrossRefPubMed
15.
go back to reference Andersson E, Swärd C, Stenman G, Ahlman H, Nilsson O: High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids. Endocr Relat Cancer. 2009, 16 (3): 953-966. 10.1677/ERC-09-0052.CrossRefPubMed Andersson E, Swärd C, Stenman G, Ahlman H, Nilsson O: High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids. Endocr Relat Cancer. 2009, 16 (3): 953-966. 10.1677/ERC-09-0052.CrossRefPubMed
16.
go back to reference Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA: High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chr & Cancer. 2008, 47 (7): 591-603. 10.1002/gcc.20561.CrossRef Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA: High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chr & Cancer. 2008, 47 (7): 591-603. 10.1002/gcc.20561.CrossRef
17.
go back to reference Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, et al: A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer. 2011, 18 (1): 171-180. 10.1677/ERC-10-0248.CrossRefPubMedPubMedCentral Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, et al: A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocr Relat Cancer. 2011, 18 (1): 171-180. 10.1677/ERC-10-0248.CrossRefPubMedPubMedCentral
18.
go back to reference Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009, 90 (2): 162-166. 10.1159/000182196.CrossRefPubMed Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, et al: ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009, 90 (2): 162-166. 10.1159/000182196.CrossRefPubMed
19.
go back to reference Rindi G, Bordi C, La Rosa S, Solcia E, Delle Fave G, Gruppo Italiano Patologi Apparato D, Societa Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology Id: Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report. Dig liver Dis. 2011, 43 (Suppl 4): S356-S360.CrossRefPubMed Rindi G, Bordi C, La Rosa S, Solcia E, Delle Fave G, Gruppo Italiano Patologi Apparato D, Societa Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology Id: Gastroenteropancreatic (neuro)endocrine neoplasms: the histology report. Dig liver Dis. 2011, 43 (Suppl 4): S356-S360.CrossRefPubMed
20.
go back to reference Weng WH, Claviez A, Krams M, Hashemi J, Larsson O, Larsson C, Suttorp M: A 10-year-old girl with bifocal synovial sarcoma. Lancet Oncol. 2006, 7 (7): 605-607. 10.1016/S1470-2045(06)70762-8.CrossRefPubMed Weng WH, Claviez A, Krams M, Hashemi J, Larsson O, Larsson C, Suttorp M: A 10-year-old girl with bifocal synovial sarcoma. Lancet Oncol. 2006, 7 (7): 605-607. 10.1016/S1470-2045(06)70762-8.CrossRefPubMed
21.
go back to reference Hashemi J, Worrall C, Vasilcanu D, Fryknas M, Sulaiman L, Karimi M, Weng WH, Lui WO, Rudduck C, Axelson M, et al: Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP). PLoS One. 2011, 6 (3): e14757-10.1371/journal.pone.0014757.CrossRefPubMedPubMedCentral Hashemi J, Worrall C, Vasilcanu D, Fryknas M, Sulaiman L, Karimi M, Weng WH, Lui WO, Rudduck C, Axelson M, et al: Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP). PLoS One. 2011, 6 (3): e14757-10.1371/journal.pone.0014757.CrossRefPubMedPubMedCentral
22.
go back to reference Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C: Bioarray software environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol. 2002, 3 (8): 1-0003.6. SOFTWARE0003CrossRef Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C: Bioarray software environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol. 2002, 3 (8): 1-0003.6. SOFTWARE0003CrossRef
23.
go back to reference Rouveirol C, Stransky N, Hupe P, Rosa PL, Viara E, Barillot E, Radvanyi F: Computation of recurrent minimal genomic alterations from array-CGH data. Bioinformatics. 2006, 22 (7): 849-856. 10.1093/bioinformatics/btl004.CrossRefPubMed Rouveirol C, Stransky N, Hupe P, Rosa PL, Viara E, Barillot E, Radvanyi F: Computation of recurrent minimal genomic alterations from array-CGH data. Bioinformatics. 2006, 22 (7): 849-856. 10.1093/bioinformatics/btl004.CrossRefPubMed
24.
go back to reference Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, et al: TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003, 34 (2): 374-378.PubMed Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, et al: TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003, 34 (2): 374-378.PubMed
25.
go back to reference do Kim H, Nagano Y, Choi IS, White JA, Yao JC, Rashid A: Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes, Chr & Cancer. 2008, 47 (1): 84-92. 10.1002/gcc.20510.CrossRef do Kim H, Nagano Y, Choi IS, White JA, Yao JC, Rashid A: Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors. Genes, Chr & Cancer. 2008, 47 (1): 84-92. 10.1002/gcc.20510.CrossRef
26.
go back to reference Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, Zhang L, Thorland EC, Minn KT, Tentu R, et al: The genomic landscape of small intestine neuroendocrine tumors. J clin Invest. 2013, 123 (6): 2502-2508. 10.1172/JCI67963.CrossRefPubMedPubMedCentral Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, Zhang L, Thorland EC, Minn KT, Tentu R, et al: The genomic landscape of small intestine neuroendocrine tumors. J clin Invest. 2013, 123 (6): 2502-2508. 10.1172/JCI67963.CrossRefPubMedPubMedCentral
27.
go back to reference Mongiat M, Ligresti G, Marastoni S, Lorenzon E, Doliana R, Colombatti A: Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2. Mol and Cell Biol. 2007, 27 (20): 7176-7187. 10.1128/MCB.00696-07.CrossRef Mongiat M, Ligresti G, Marastoni S, Lorenzon E, Doliana R, Colombatti A: Regulation of the extrinsic apoptotic pathway by the extracellular matrix glycoprotein EMILIN2. Mol and Cell Biol. 2007, 27 (20): 7176-7187. 10.1128/MCB.00696-07.CrossRef
28.
go back to reference Hill VK, Hesson LB, Dansranjavin T, Dallol A, Bieche I, Vacher S, Tommasi S, Dobbins T, Gentle D, Euhus D, et al: Identification of 5 novel genes methylated in breast and other epithelial cancers. Molecular cancer. 2010, 9: 51-10.1186/1476-4598-9-51.CrossRefPubMedPubMedCentral Hill VK, Hesson LB, Dansranjavin T, Dallol A, Bieche I, Vacher S, Tommasi S, Dobbins T, Gentle D, Euhus D, et al: Identification of 5 novel genes methylated in breast and other epithelial cancers. Molecular cancer. 2010, 9: 51-10.1186/1476-4598-9-51.CrossRefPubMedPubMedCentral
29.
go back to reference Messahel B, Williams R, Ridolfi A, A’Hern R, Warren W, Tinworth L, Hobson R, Al-Saadi R, Whyman G, Brundler MA, et al: Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a children’s cancer and leukaemia group (CCLG) Study. Eur J Cancer. 2009, 45 (5): 819-826. 10.1016/j.ejca.2009.01.005.CrossRefPubMed Messahel B, Williams R, Ridolfi A, A’Hern R, Warren W, Tinworth L, Hobson R, Al-Saadi R, Whyman G, Brundler MA, et al: Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a children’s cancer and leukaemia group (CCLG) Study. Eur J Cancer. 2009, 45 (5): 819-826. 10.1016/j.ejca.2009.01.005.CrossRefPubMed
30.
go back to reference Hajra KM, Fearon ER: Cadherin and catenin alterations in human cancer. Genes, Chr & Cancer. 2002, 34 (3): 255-268. 10.1002/gcc.10083.CrossRef Hajra KM, Fearon ER: Cadherin and catenin alterations in human cancer. Genes, Chr & Cancer. 2002, 34 (3): 255-268. 10.1002/gcc.10083.CrossRef
31.
go back to reference Moran CJ, Joyce M, McAnena OJ: CDH1 associated gastric cancer: a report of a family and review of the literature. EJSO. 2005, 31 (3): 259-264. 10.1016/j.ejso.2004.12.010.CrossRefPubMed Moran CJ, Joyce M, McAnena OJ: CDH1 associated gastric cancer: a report of a family and review of the literature. EJSO. 2005, 31 (3): 259-264. 10.1016/j.ejso.2004.12.010.CrossRefPubMed
32.
go back to reference Edstrom E, Mahlamaki E, Nord B, Kjellman M, Karhu R, Hoog A, Goncharov N, Teh BT, Backdahl M, Larsson C: Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am J Pathol. 2000, 156 (2): 651-659. 10.1016/S0002-9440(10)64769-4.CrossRefPubMedPubMedCentral Edstrom E, Mahlamaki E, Nord B, Kjellman M, Karhu R, Hoog A, Goncharov N, Teh BT, Backdahl M, Larsson C: Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am J Pathol. 2000, 156 (2): 651-659. 10.1016/S0002-9440(10)64769-4.CrossRefPubMedPubMedCentral
33.
go back to reference Ambatipudi S, Gerstung M, Gowda R, Pai P, Borges AM, Schäffer AA, Beerenwinkel N, Mahimkar MB: Genomic profiling of advanced-stage oral cancers reveals chromosome 11q alterations as markers of poor clinical outcome. PLoS One. 2011, 6 (2): e17250-10.1371/journal.pone.0017250.CrossRefPubMedPubMedCentral Ambatipudi S, Gerstung M, Gowda R, Pai P, Borges AM, Schäffer AA, Beerenwinkel N, Mahimkar MB: Genomic profiling of advanced-stage oral cancers reveals chromosome 11q alterations as markers of poor clinical outcome. PLoS One. 2011, 6 (2): e17250-10.1371/journal.pone.0017250.CrossRefPubMedPubMedCentral
34.
go back to reference Spitz R, Hero B, Simon T, Berthold F: Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res. 2006, 12 (11 Pt 1): 3368-3373.CrossRefPubMed Spitz R, Hero B, Simon T, Berthold F: Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res. 2006, 12 (11 Pt 1): 3368-3373.CrossRefPubMed
35.
go back to reference Giaretti W, Maffei M, Pentenero M, Scaruffi P, Donadini A, Di Nallo E, Malacarne D, Marino R, Familiari U, Coco S, et al: Genomic aberrations in normal appearing mucosa fields distal from oral potentially malignant lesions. Cell Oncol. 2012, 35 (1): 43-52. 10.1007/s13402-011-0064-2.CrossRef Giaretti W, Maffei M, Pentenero M, Scaruffi P, Donadini A, Di Nallo E, Malacarne D, Marino R, Familiari U, Coco S, et al: Genomic aberrations in normal appearing mucosa fields distal from oral potentially malignant lesions. Cell Oncol. 2012, 35 (1): 43-52. 10.1007/s13402-011-0064-2.CrossRef
36.
go back to reference Bae JS, Choi JS, Baik SH, Park WC, Song BJ, Kim JS, Lim Y, Jung SS: Genomic alterations of primary tumor and blood in invasive ductal carcinoma of breast. World J Surg Oncol. 2010, 8: 32-10.1186/1477-7819-8-32.CrossRefPubMedPubMedCentral Bae JS, Choi JS, Baik SH, Park WC, Song BJ, Kim JS, Lim Y, Jung SS: Genomic alterations of primary tumor and blood in invasive ductal carcinoma of breast. World J Surg Oncol. 2010, 8: 32-10.1186/1477-7819-8-32.CrossRefPubMedPubMedCentral
37.
go back to reference Buffart TE, van Grieken NC, Tijssen M, Coffa J, Ylstra B, Grabsch HI, van de Velde CJ, Carvalho B, Meijer GA: High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch. 2009, 455 (3): 213-223. 10.1007/s00428-009-0814-y.CrossRefPubMedPubMedCentral Buffart TE, van Grieken NC, Tijssen M, Coffa J, Ylstra B, Grabsch HI, van de Velde CJ, Carvalho B, Meijer GA: High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch. 2009, 455 (3): 213-223. 10.1007/s00428-009-0814-y.CrossRefPubMedPubMedCentral
38.
go back to reference Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R, Ke XS, Oyan AM, Kalland KH, Rotter V, et al: Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One. 2011, 6 (1): e14632-10.1371/journal.pone.0014632.CrossRefPubMedPubMedCentral Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R, Ke XS, Oyan AM, Kalland KH, Rotter V, et al: Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One. 2011, 6 (1): e14632-10.1371/journal.pone.0014632.CrossRefPubMedPubMedCentral
39.
go back to reference Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, et al: Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A. 2000, 97 (3): 1230-1235. 10.1073/pnas.97.3.1230.CrossRefPubMedPubMedCentral Bai C, Connolly B, Metzker ML, Hilliard CA, Liu X, Sandig V, Soderman A, Galloway SM, Liu Q, Austin CP, et al: Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A. 2000, 97 (3): 1230-1235. 10.1073/pnas.97.3.1230.CrossRefPubMedPubMedCentral
40.
go back to reference Liang QL, Wang BR, Li GH: DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B. 2009, 10 (9): 675-682. 10.1631/jzus.B0920077.CrossRefPubMedPubMedCentral Liang QL, Wang BR, Li GH: DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B. 2009, 10 (9): 675-682. 10.1631/jzus.B0920077.CrossRefPubMedPubMedCentral
41.
go back to reference Wu Y, Guo E, Yu J, Xie Q: High DcR3 expression predicts stage pN2-3 in gastric cancer. Am J Clin Oncol. 2008, 31 (1): 79-83. 10.1097/COC.0b013e3180ca77ad.CrossRefPubMed Wu Y, Guo E, Yu J, Xie Q: High DcR3 expression predicts stage pN2-3 in gastric cancer. Am J Clin Oncol. 2008, 31 (1): 79-83. 10.1097/COC.0b013e3180ca77ad.CrossRefPubMed
Metadata
Title
Copy number alterations in small intestinal neuroendocrine tumors determined by array comparative genomic hybridization
Authors
Jamileh Hashemi
Omid Fotouhi
Luqman Sulaiman
Magnus Kjellman
Anders Höög
Jan Zedenius
Catharina Larsson
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-505

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine